Drug General Information (ID: DDIK9YBM1R)
Drug Name			Glimepiride		Drug Info		Metreleptin		Drug Info
Drug Type		Small molecule				Hormones
Therapeutic Class		Antidiabetic Agents				Metabolic Agents

Mechanism of Glimepiride-Metreleptin Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Glimepiride				Metreleptin
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Glimepiride and Metreleptin

Recommended Action
Management		Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

References
1	Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
2	Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
3	Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72. [PMID: 6781341]